On February 24, 2022 GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company’s proprietary natural killer (NK) cell engager, TriKE protein biologic technology platform, reported that GT Biopharma will be participating in the following upcoming medical conferences (Press release, GT Biopharma, FEB 24, 2022, View Source [SID1234609014]):
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Abstract and poster presentation details are as follows:
ESMO Targeted Anticancer Therapies Congress (TAT) (March 7-8, 2022)
Title:
Driving NK cell immunotherapy against NSCLC, in the context of hypoxia, using Tri-specific Killer Engager (TriKE)
Abstract Number:
250
Session:
Immunotherapy
Presentation Type:
Poster
Session Date and Time:
March 7, 9:20AM (CET) (On-demand e-poster display)
Location:
Virtual
Poster Board Number:
17P
48th Annual European Society for Blood and Marrow Transplantation (EBMT) (March 19-23, 2022)
Title:
A Tri-specific Killer Engager (TriKE) against B7-H3 enhances NK cell mediated killing of multiple myeloma
Abstract Number:
AS-EBMT-2022-00508
Session:
New Drugs- and Cell-Based Immune Therapies
Presentation Type:
Poster
Session Date and Time:
March 19, 2022, 9:50 AM (CET)
Location:
Prague Congress Center, Czech Republic
Poster Board Number:
P153
American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting (April 8-13, 2022)
Title:
GTB-5550 (cam16-IL15-camB7H3) Tri-specific Killer Engager (TriKE) drives natural killer cell activation and antibody dependent cellular cytotoxicity against head and neck squamous cell carcinomas
Abstract Number:
Abstract control number 3334, permanent abstract number 3435
Session:
Clinical Research Excluding Trials, Combination Immunotherapies / Therapeutic Antibodies
Presentation Type:
Poster
Session Date and Time:
April 12, 2022 1:30 PM – 5:00 PM
Location:
Ernest N. Memorial Convention Center, Exhibit Halls D-H, Poster Section 32, New Orleans
Poster Board Number:
16